Search

Complete abstract information will be provided to the CMSC Annual Meeting attendees on May 28, 2023.

CMSC Abstracts Search Form (Titles and Authors only)

Search Accepted Abstracts
Sending

Search Results

Year ID Type Category Title Authors
2021 Late-Breaking Disease-modifying therapy

Lowered COVID-19 mRNA Vaccine Antibody Response in MS Patients Treated with B -Cell Depleting and S1P-Receptor-Targeting Therapies Compared to Controls: An Interim Analysis

T. Chitnis, S. Conway, M. Houtchens, B. Glanz, M. Polgar-Turcsanyi, T. J. Saraceno, P. Gaitan-Walsh, E. C. Casady, S. Winston-Khan, T. Feldman, E. Sanon, M. Weiner, R. Bakshi, S. Bhattacharyya, G. Bose, K. Galetta, T. Kaplan, C. A. Severson, T. Singhal, L. Stazzone, J. Zurawski, S. Saxena, A. Loven, F. Yusuf, A. Paul, B. C. Healy, and H. L. Weiner

2021 Late-Breaking Case Reports/Case Series

Brief Telehealth Screening of MS Patients in the Medical Setting

C. S. Bergmann, D. Jackson, R. Render, M. E. Quig, R. L. Kane, M. A. Adamson, and J. Simsarian

2021 Late-Breaking Disease-modifying therapy

Variables Affecting Disease Modifying Therapy Adherence and Impact of Adherence on Multiple Sclerosis Patients (Egyptian experience)

A. Abdelsalam, R. Elkabany, I. Alahmar, and M. Sabry

2021 Late-Breaking Disease-modifying therapy

B-Cell Depleters Attenuate the Humoral Response to Sars-Cov-2 Vaccines in Multiple Sclerosis Patients: A Case-Control Study

W. L. Conte

2021 Late-Breaking Disease-modifying therapy

Primary Results of NOVA: A Randomized Controlled Study of the Efficacy of 6 Week Dosing of Natalizumab Versus Continued 4-Week Treatment

J. Foley, G. Defer, L. Zhovtis Ryerson, J. A. Cohen, D. L. Arnold, H. Butzkueven, G. Cutter, G. Giovannoni, J. Killestein, H. Wiendl, K. Smirnakis, S. Xiao, G. Kong, R. Kuhelj, and N. Campbell

2021 Late-Breaking Disease-modifying therapy

COVID-19 Vaccine Antigenicity in the Setting of MS Disease Modifying Treatments

H. Noh, T. Mortensen, and R. H. Dave

2021 CAM01 Poster Complementary and Alternative Therapies

Remote Art Therapy Activities Proposal during a COVID-19 Pandemic in Multiple Sclerosis

2021 CAM02 Poster Complementary and Alternative Therapies

Evaluation of a 6 Week Integrative Medicine Workshop Series on Quality of Life, Self-Efficacy and Wellness in MS

Megan Weigel, DNP, APRN, MSCN, APHN1,2,3, Linda Connelly, PhD, MSH, ARNP, CNOR1 and Mehgan Fox, BSH2, (1)Brooks College of Health, School of Nursing, University of North Florida, Jacksonville, FL, (2)First Coast Integrative Medicine, Jacksonville, FL, (3)oMS Yoga, Inc., Jacksonville Beach, FL

2021 CAM03 Poster Complementary and Alternative Therapies

Mindfulness Based Art Therapy to Improve Symptoms Among Adults with Multiple Sclerosis

Pamela K Newland, PhD, RN, Goldfarb School of Nursing, St Louis, IL, Karlie Lading, BS, RN, nursing, Goldfarb School of Nursing, St Louis, MO and Ling Chen, PhD, Biostatistics, Washington University St Louis, St Louis, MO

2021 CSR01 Poster Case Reports / Case Series

Delayed Visual Improvement in Pediatric Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis

Alexandra B Kornbluh, MD1, Grant T Liu, MD2 and Sarah E Hopkins, MD, MSPH1, (1)Neurology, Children’s Hospital of Philadelphia, Philadelphia, PA, (2)Ophthalmology, Children’s Hospital of Philadelphia, Philadelphia, PA

2021 CSR02 Poster Case Reports / Case Series

Non-Intensive Exercise to Prepare for Intensive, Task-Oriented Rehabilitation in People with Progressive Multiple Sclerosis: A Two-Participant Case Study

Cameron S Mang, PhD1, Kristen E Plandowski, BSc1, Eduardo A Toledo-Aldana, BSc1 and Sarah J Donkers, PT, PhD2, (1)Kinesiology and Health Studies, University of Regina, Regina, SK, Canada, (2)School of Rehabilitation Science, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada

2021 CSR03 Poster Case Reports / Case Series

Long Arm Serial Casting Results in Decreased Spasticity and Improved Function for Woman with MS

Christine Hampton, MOT, OTR/L, Shepherd Center, Atlanta, GA

2021 CSR04 Poster Case Reports / Case Series

Positive Outcome with Alemtuzumab in Hispanic Puerto Rican Woman with Highly Active Multiple Sclerosis after Various Failed Disease Modifying Therapies

2021 CSR05 Poster Case Reports / Case Series

Immunotherapy-Responsive Post COVID-19 Central Nervous System Inflammatory Syndrome, a Case Report

Gina S Perez, MD, Courtney Iser, MD, Sara Habib, MD, Juliane Chainakul, APRN-CNS, Sarah Durica, MD, Danny Samkutty, MD, Evgeny Sidorov, MD, Ahmad Al Awwad, MD, Masoom Desai, MD, Jorge Ortiz, MD, Nidhiben Anadani, MD and David Gordon, MD, Neurology, University of Oklahoma Health Sciences Center, Oklahoma City, OK

2021 CSR06 Poster Case Reports / Case Series

Case Report: Lama-2 Related Muscular Dystrophy Mimicking Multiple Sclerosis

Jacqueline Koshorek, DO and Shiv Saidha, MBBCh, MD, MRCPI, Neurology, Johns Hopkins University, Baltimore, MD

2021 CSR07 Poster Case Reports / Case Series

Case Report of a Severe Cutaneous Lupus Erythematosus Flare in a Patient Treated with Eculizumab for the Treatment of Neuromyeltis Optica Spectrum Disorder

Jennifer Chester, FNP-BC, MSCN1, Leah Hurd, RN, BSN2, Tyler Kaplan, MD3,4, Mark Box, MD5 and Jeffrey Kaplan, MD2, (1)Kansas City MS Center at College Park Specialty, Overland Park, KS, (2)Kansas City MS Center, College Park Neurology, Overland Park, KS, (3)Rush University Medical Center, Chicago, United States Minor Outlying Islands, (4)University of Utah, Salt Lake City, UT, (5)Rheumatology, Carondolet, Kansas City, MO

2021 CSR08 Poster Case Reports / Case Series

Bad Lettuce? Frozen Vegetables? Undercooked Steak? Case Report of Systemic Listeria Monocytogenes Infection in a Patient on Dimethyl Fumarate

Lisa M. Fox, PA-C MPAS, Neurology/Neuroimmunology, Johns Hopkins Medical Center, Baltimore, MD and Scott D. Newsome, DO, MSCS, FAAN, FANA, Neurology, Johns Hopkins University School of Medicine, Baltimore, MD

2021 CSR09 Poster Case Reports / Case Series

Treatment Resistant Tinea Corporis in Multiple Sclerosis Patients Treated with Ocrelizumab

Michelle Maynard, PharmD, BCPS, Neurosciences, Froedtert and the Medical College of Wisconsin, Milwaukee, WI, Carmen Raschka, RN, Neurosciences, Froedtert Hospital, Milwaukee, WI, Mokshal H Porwal, BSc, Medical College of Wisconsin, Milwaukee, WI and Ahmed Z Obeidat, MD, PhD, Department of Neurology, Medical College of Wisconsin, Milwaukee, WI

2021 CSR10 Poster Case Reports / Case Series

Identifying and Treating Steroid-Induced Psychosis in MS Patients Using Quetiapine

Olinka K Hrebicek, MD, Neurology, Island Health MS Clinic, Victoria, BC, Canada and Niall I Murphy, BSc, University of Victoria, Victoria, BC, Canada

2021 CSR11 Poster Case Reports / Case Series

Multiple Sclerosis-like Features in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Red Flag, Red Herring, or Regular Occurrence?

Samuel B Marcucci, BS1, Rosemarie Walch, DO1, Ameneh Zare-Shahabadi, MD/MPH2, Lawrence P Goldstick, MD1, Allison Jordan, DO1, Roman Kassa, MD/PhD1, Abdelkader Mahammedi, MD3 and Aram Zabeti, MD1, (1)Waddell Center for Multiple Sclerosis, University of Cincinnati, Cincinnati, OH, (2)Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV, (3)Department of Radiology, University of Cincinnati, Cincinnati, OH

2021 CSR12 Poster Case Reports / Case Series

Multiple Sclerosis in a Patient with Neurofibromatosis Type-1

Siddharth Ninan, MBBS1, Gershon Timothy, MD, PhD1, Robert Greenwood, MD1, Clara Zelasky, PA-C1, Stephanie Iyer, PharmD, CPP2 and Irena Dujmovic-Basuroski, MD1, (1)Department of Neurology, UNC Hospitals, Chapel Hill, NC, (2)Department of Pharmacy, UNC Hospitals, Chapel Hill, NC

2021 DMT08 Poster Disease-modifying Therapy

Evobrutinib Efficacy Is Maintained over Two Years in an Open-Label Phase II Study Extension in Patients with Relapsing Multiple Sclerosis

2021 DMT09 Poster Disease-modifying Therapy

Assessment of Composite Disability Accumulation of Ponesimod Relative to Teriflunomide in the Optimum Phase 3 Study

Alexander J. Keenan, MA, MHP, Ibrahim Turkoz, PhD, Robert Murray, MS and Maria Ait Tihyaty, PhD, Janssen Research & Development, Titusville, NJ

2021 DMT10 Poster Disease-modifying Therapy

MS Fatigue: Treatment Effect of Ponesimod in RMS Patients with and without Disease Activity

Alexander Keenan, MD1, Ibrahim Turkoz, PhD1, Robert Murray, MS2 and Maria Ait Tihyaty, PhD1, (1)Janssen Research & Development, Titusville, NJ, (2)Janssen Research & Development LLC, High Wycombe, NJ, United Kingdom

2021 DMT11 Poster Disease-modifying Therapy

Generic Perceptions: Measuring Opinions of Patients with MS Toward Generic Disease Modifying Therapies (DMTs)

Amanda Hickman, PharmD, MPH, MSCS, Central Support Team, Trellis Rx, Atlanta, GA

2021 DMT12 Poster Disease-modifying Therapy

Recently Diagnosed Treatment-Naive RRMS: 1-Year Safety Data from the Ocrelizumab Phase IIIb ENSEMBLE Study

2021 DMT13 Poster Disease-modifying Therapy

Characteristics and Outcome of COVID-19 in Patients with Relapsing Multiple Sclerosis Receiving Ofatumumab

Anne H. Cross, MD1, Silvia Delgado, MD2, Mario Habek, MD3, Maria Davydovskaya, PhD4, Natalia Totolyan, MD5, Ratnakar Pingili, MBBS6, Linda Mancione, BA6, Roseanne Sullivan, PharmD6, Martin Zalesak, MD, PhD7, Wendy Su, PhD8, Krishnan Ramanathan, PhD7, Xavier Montalban, MD, PhD9 and Kevin Winthrop, MD MPH10, (1)Neurology, Washington University School of Medicine, St Louis, MO, (2)Neurology, University of Miami Miller School of Medicine, Miami, FL, (3)University Hospital Center Zagreb, University of Zagreb, School of Medicine, Zagreb, Croatia, (4)Pirogov Russian National Research Medical University, Moscow, Russian Federation, (5)National Medical University, St Petersburg, Russian Federation, (6)Novartis Pharmaceuticals Corporation, East Hanover, NJ, (7)Novartis Pharma AG, Basel, Switzerland, (8)Autoimmune, TG Therapeutics, Inc, New York, NY, (9)Vall d’Hebron University Hospital, Barcelona, Spain, (10)School of Public Health at Oregon Health & Science University, Portland, OR

2021 DMT14 Poster Disease-modifying Therapy

Immunoglobulin Kinetics and Infection Risk after Long-Term Inebilizumab Treatment for Neuromyelitis Optica Spectrum Disorder

Benjamin Greenberg, MD1, Dewei She, Ph.D.2, Eliezer Katz, M.D.2 and Bruce A.C. Cree, MD, PhD, MAS3, (1)Department of Neurology, University of Texas Southwestern, Dallas, TX, (2)Viela Bio, Gaithersburg, MD, (3)Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA

2021 DMT15 Poster Disease-modifying Therapy

Long-Term Efficacy and Safety of Siponimod in Active SPMS and Overall SPMS Populations: Expand Study Data up to 5 Years

Bruce A.C. Cree, MD, PhD, MAS1, Gavin Giovannoni, MD, PhD2, Ralf Gold, MD3, Robert J. Fox, MD4, Patrick Vermersch, MD, PhD5, Ralph H.B. Benedict, PhD6, Amit Bar-Or, MD7, Nicolas Rouyrre, MSc8, Daniela Piani-Meier, PhD8, Shannon Ritter, MS9, Ajay Kilaru, MBBS8, Frank Dahlke, MD8, Goeril Karlsson, PhD8 and Ludwig Kappos, MD10, (1)Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, (2)Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, (3)Department of Neurology, St Josef-Hospital, Ruhr-University Bochum, Bochum, Germany, (4)Mellen Center for Treatment and Research in Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland, OH, (5)Univ. Lille, Inserm U1172, CHU Lille, FHU Precise, Lille, France, (6)Jacobs Multiple Sclerosis Center, University at Buffalo, Buffalo, NY, (7)Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, (8)Novartis Pharma AG, Basel, Switzerland, (9)Novartis Pharmaceuticals Corporation, East Hanover, NJ, (10)Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland

2021 DMT16 Poster Disease-modifying Therapy

Effect of Age on the Change of Lymphocytes and Immunoglobulins during Treatment with Ocrelizumab or Rituximab for Multiple Sclerosis and Related Disorders

Calin Dumitrescu, Medical Student Scholar, Neurology, Medical College of Wisconsin, Milwaukee, WI, Amber Salter, PhD, Biostatistics, Washington University in St. Louis, St. Louis, MO, Michelle Maynard, PharmD, BCPS, Neurosciences, Froedtert and the Medical College of Wisconsin, Milwaukee, WI and Ahmed Z Obeidat, MD, PhD, Department of Neurology, Medical College of Wisconsin, Milwaukee, WI

2021 DMT17 Poster Disease-modifying Therapy

Safety of Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis with Suboptimal Response to Prior Disease-Modifying Therapies: Data from the CASTING Study

2021 DMT18 Poster Disease-modifying Therapy

Baseline Characteristics and Adherence Among Multiple Sclerosis Patients Initiating Siponimod in Real World

Chinmay Deshpande, PhD, BPharm1, Mengru Wang, MS2, Roshani Shah, MPH3, Yutong Chang, MS2, Fei Yang, PhD1, Wing Chow, PharmD, MPH1 and Gina M Cox, PhD1, (1)Novartis Pharmaceuticals Corporation, East Hanover, NJ, (2)KMK Consulting, Inc., Morristown, NJ, (3)Previously employed by Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, NJ

2021 DMT19 Poster Disease-modifying Therapy

Daniel Kantor, MD1, Timothy Pham, MS2, Xiu Chen, PhD2, Mayank Mittal, PhD2 and Qian Xia, PhD2, (1)Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL, (2)Bristol Myers Squibb, Princeton, NJ

2021 DMT20 Poster Disease-modifying Therapy

Number-Needed-to-Treat (NNT) to Prevent One Relapse in Recent Teriflunomide-Controlled Clinical Trials in Relapsing MS

Daniel Kantor, MD, Florida Atlantic University, Boca Raton, FL

2021 DMT21 Poster Disease-modifying Therapy

Number-Needed-to-Harm (NNH) in Alemtuzumab and Ocrelizumab Pivotal Clinical Trials in Relapsing MS

Daniel Kantor, MD, Florida Atlantic University, Boca Raton, FL

2021 DMT22 Poster Disease-modifying Therapy

Click-MS: Cladribine Tablets in Patients with Relapsing Multiple Sclerosis after Suboptimal Response to Prior Injectable Disease-Modifying Therapy (Interim Analysis 1)

Augusto A Miravalle, M.D., Advanced Neurology of Colorado, University of Colorado, Fort Collins, CO, Jacob A Sloane, MD PhD, BIDMC Department of Neurology, Harvard Medical School, Boston, MA, Julie Aldridge, MS, EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany, Billerica, MA, Danielle E Harlow, PhD, EMD Serono, Inc., Rockland, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany, Rockland, MA and Joshua D Katz, M.D., The Elliot Lewis Center for Multiple Sclerosis Care, Wellesley, MA

2021 DMT23 Poster Disease-modifying Therapy

Long-Term Efficacy and Safety of Eculizumab in AQP4+ Neuromyelitis Optica Spectrum Disorder

Dean Wingerchuk, M.D.1, Achim Berthele, MD2, Kazuo Fujihara, MD3,4,5, Celia Oreja-Guevara, MD6, Ho Jin Kim, MD, PhD7, Michael Levy, MD, PhD8,9, Ichiro Nakashima, MD, PhD4,10, Jacqueline Palace, DM11, Shulian Shang, PhD12, Marcus Yountz, MD12, Larisa Miller, PharmD12 and Sean J Pittock, M.D.13, (1)Mayo Clinic, Scottsdale, AZ, (2)Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany, (3)Southern TOHOKU Research Institute for Neuroscience (STRINS), Koriyama, Japan, (4)Tohoku University, Sendai, Japan, (5)Fukushima Medical University, Fukushima City, Japan, (6)Hospital Universitario Clinico San Carlos, Madrid, Spain, (7)Research Institute and Hospital, National Cancer Center, Goyang, Korea, Republic of (South), (8)Massachusetts General Hospital and Harvard Medical School, Boston, MA, (9)Johns Hopkins University, Baltimore, MD, (10)Tohoku Medical and Pharmaceutical University, Sendai, Japan, (11)John Radcliffe Hospital, Oxford, United Kingdom, (12)Alexion Pharmaceuticals, Boston, MA, (13)Mayo Clinic, Rochester, MN

2021 DMT24 Poster Disease-modifying Therapy

Analysis of Health Care Provider Reasons for Switching to Diroximel Fumarate from Other Disease-Modifying Therapies

Denise R. Bruen, MSN1, Meghan Garabedian, CRNP, MSN, MSCN2, Cortnee Roman, MSN, FNP-BC3, Nicholas W. Robinson, MA4, Virginia R. Schobel, MSc4, Jason P. Mendoza, PhD5, James B. Lewin, PharmD5, Mary Zhang, PharmD5 and Sai L. Shankar, PhD5, (1)University of Virginia Neuroscience, Charlottesville, VA, (2)Neurology, Penn Neuroscience Center, Perelmen Center for Advanced Medicine, Philadelphia, PA, (3)Rocky Mountain Multiple Sclerosis Clinic and Research Group, Salt Lake City, UT, (4)Spherix Global Insights, Exton, PA, (5)Biogen, Cambridge, MA

2021 DMT25 Poster Disease-modifying Therapy

Whole Brain, Cortical Grey Matter, and Thalamic Volume Changes during 3 to 5 Years of Ozanimod in Relapsing MS

2021 DMT26 Poster Disease-modifying Therapy

Acapella: Real-World Experience with Ocrelizumab: An Observational Study Evaluating Safety in Patients with Relapsing and Progressive MS, Year Four Data

Elizabeth A Douglas, MPH, Rosie M Jungquist, B.S., Andrew J Bouley, M.D., Ellen S Lathi, M.D. and Joshua D Katz, M.D., The Elliot Lewis Center for Multiple Sclerosis Care, Wellesley, MA